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Abstract
Despite rapid advances in genome engineering technologies, inserting genes into precise locations
in the human genome remains an outstanding problem. It has been suggested that site-specific
recombinases can be adapted towards use as transgene delivery vectors. The specificity of
recombinases can be altered either with directed evolution or via fusions to modular DNA-binding
domains. Unfortunately, both wildtype and altered variants often have detectable activities at off-
target sites. Here we use bacterial selections to identify mutations in the dimerization surface of
Cre recombinase (R32V, R32M, and 303GVSdup) that improve the accuracy of recombination.
The mutants are functional in bacteria, in human cells, and in vitro (except for 303GVSdup, which
we did not purify), and have improved selectivity against both model off-target sites and the entire
E. coli genome. We propose that destabilizing binding cooperativity may be a general strategy for
improving the accuracy of dimeric DNA-binding proteins.
Introduction
Safe delivery of transgenes into the human genome remains an open problem of critical
importance to clinical genetics. Many existing technologies have major limitations. For
instance, retroviruses, lentiviruses, and transposons integrate non-specifically and can
therefore cause cancer by mutagenesis1,2. Transgenes can also be integrated using the
endogenous homologous repair pathways, although this process must be stimulated by
generating double-stranded breaks at the target site using programmable nuclease
technologies such as meganucleases3, zinc finger nucleases4, TALE nucleases5,6, or the
RNA-guided Cas9 protein7,8. This technique is limited by the fact that homologous
recombination in humans is less efficient than the competing mutagenic non-homologous
end joining pathway9,10.
Site-specific recombinases, which catalyze recombination at precise sites, have properties
that make them promising candidates for use as safe gene delivery vectors. For instance,
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tmany do not require host-encoded factors11. Additionally, the size of the integrated cassette
is less restricted than for other methods. Recombinases’ specificities can be altered either by
direction evolution or by fusion to modular DNA-binding domains12–20. Unfortunately,
many reprogrammed variants are promiscuous in their activity. This problem isn’t restricted
to artificial variants, as activity at off-target human genomic loci has been reported for some
wild-type (WT) recombinases21–24. If recombinases are to be used as gene delivery vectors,
it is imperative to identify ways to enhance their accuracy.
The accuracy of DNA-binding proteins can be altered by varying the ratio of specific to non-
specific DNA-protein interactions25. While powerful, this approach can be inconvenient if
the goal is to generate variants of a protein with different specificities: a specificity change
alters the DNA-protein interaction, requiring re-optimization of accuracy. Therefore, there is
a need for methods to systematically enhance accuracy without changing the DNA-protein
interface.
In this work we attempt to discern such principles using Cre recombinase of the phage P1 as
a model system. Cre catalyzes a reversible, directional recombination between two 34 base-
pair (bp) loxP sites that consist of a pair of 13 bp inverted repeats flanking an 8 bp
asymmetrical spacer26–28. Mutagenic studies of loxP have shown that many mutations have
non-catastrophic effects on recombination efficiency29–31. Using a theoretical model we
predict that reducing the cooperativity of binding should increase accuracy. We mutagenize
a region involved in the formation of Cre dimers and perform bacterial selections for
functional and accurate mutants. We isolate three mutants, all of which were able to
recombine loxP sites with high efficiency and exhibited improved accuracy with respect to
both model off-target sites and the entire E. coli genome.
Results
A theoretical model of DNA binding accuracy
Under the currently accepted mechanism of Cre recombination, the binding of a Cre
monomer to one half of a loxP site is followed by the formation of an asymmetrical
homodimer when a second Cre molecule binds to the other half of loxP. Next, the two loxP-
bound dimers associate to form a tetramer, and recombination proceeds via a Holiday
Junction intermediate28. We reasoned that the formation of the dimer of dimers is not site
specific in the sense that it involves no new DNA binding events, leading us to conclude that
the precision of dimer formation determines the accuracy of recombination. Dimer
formation on target sites is described with:
(1)
(2)
where P is the unbound protein monomer, D is the full DNA binding site, K is the affinity of
each monomer for half of the binding site, and Kdim is the affinity of the protein dimer for
the full binding site. If it is assumed that the cooperative energy is sequence-independent
then Kdim = KKcoop, where Kcoop is the protein-protein affinity. A competing set of binding
events occurs between off-target DNA and the protein:
(3)
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where [DOT] is the off-target DNA concentration and KOT is the affinity of the protein for
off-target DNA. Accuracy can be defined as the ratio of on-target protein dimers to off-
target protein dimers:
(5)
The free DNA concentration [D] is related to the total DNA concentrations [Dtotal] via:
(6)
An analogous expression relates [DOT] and [DOT,total]. Equation (5) can be expressed in
terms of total DNA concentrations:
(7)
To model accuracy of Cre in E. coli we used the in vitro affinity coefficients K of 1.5 × 108
M−1 and a Kcoop of 1.7 × 103 M−1, with both values obtained from previous in vitro
measurements32. We assumed that K/KOT = 104, which is in the same order of magnitude as
the experimentally determined K/KOT of EcoRV and BamHI33. Assuming a single target site
in an E. coli cell of a 0.5 μm radius gives a [Dtotal] of 3.2 × 10−9 M. If off-target sites exist
at 1bp windows along both strands of the 4.6 Mbp E. coli genome then [DOT,total] is
approximately 3.2 × 10−9 M bp−1 * 9.2 ×106 bp = 2.9 × 10−2 M. This value of [DOT,total]
may be an overestimate due to competitive binding of other DNA-associated proteins to the
genome.
We plotted the predicted accuracy of dimer formation as a function of total protein
concentration for both WT Cre and for mutants with reduced cooperativity (Fig. 1). The
model predicts that accuracy increases with both a reduction in cooperativity and a decrease
in protein expression levels. This is an intuitive result because accuracy should increase as
the two monomer binding events become more independent from each other. We conclude
that while a reduction in cooperatively will affect both target and off-target binding, off-
target binding will be destabilized to a greater degree.
Identifying candidate mutations using bacterial selection
Our theoretical model predicted that accuracy could be improved by decreasing the
cooperative binding moment. We therefore targeted our mutagenesis towards a domain
directly involved in the dimer interaction but distant from the Cre-DNA interaction: the
alpha helix closest to the amino-terminus34. To find mutations that improve accuracy while
maintaining proper function with respect to loxP we performed two rounds of bacterial
selection. The first round was designed to identify functional mutants while the second
round selected accurate mutants. To select functional mutants we used a resistance marker
flanked by loxP sites in an inverted orientation relative to each other. The reading frame was
inverted with respect to the promoter, such that Cre-mediated inversion would result in gain
of antibiotic resistance. An out-of-frame toxic ccdB was used to apply a selective pressure
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tagainst inaccurate recombination reactions that produced frame-shifts (Fig. 2a). To
minimize false negatives due to reversal of the inversion we placed the selection cassette on
a high copy plasmid. The selection resulted in the recovery of 1,690 library-transformed
colonies, which corresponds to 38% of the total transformation efficiency. The library
produced fewer clones than the positive WT control, suggesting that the selection is
functional (Fig. 2b).
To identify accurate constructs we first found an off-target site to serve as bait in the
negative selection. To achieve a high selective pressure we wanted a bait sequence that
would be recombined with a high efficiency. At the same time, we wanted to select for
improved accuracy across the entire protein-DNA interaction, and therefore we wanted a
bait sequence with little similarity to loxP. We found such a site by performing a selection
for pseudo-loxP sites and characterizing their in vitro recombination efficiency. The site,
which we named loxBait, is recombined with 37% the efficiency of *loxP* despite
differences in 9 out of 13 bases within a single inverted repeat (Figs. 3a and 3b).
We performed the counter-selection by flanking an in-frame antibiotic resistance marker
with loxBait and loxP oriented in the same direction. The toxic ccdB gene was placed 3′ of
loxP. Cre-mediated excision would result in both loss of the resistance marker and
expression of the toxic gene (Fig. 2c). We subjected the expression plasmids recovered from
the positive selection to one round of counter-selection. In this case the catalytically inactive
mutant, Y324F, served as the control for growth without selection (Fig. 2d).
We randomly isolated two of the recovered mutants, R32V and R32M, for further
characterization. R32 is involved in an inter-monomer salt bridge with E69, so its disruption
in the two mutants can be expected to reduce the protein-protein affinity (Fig. 4a). Two WT
colonies survived the counter-selection, one of which contained a clone with a de novo
duplication of residues 303–305 (303GVSdup). This region is a loop that makes close
contact to the other monomer in the dimer structure (Fig. 4b).
Mutants better discriminate a model off-target site
We measured the activity of Cre and the isolated mutants on loxP and ψLox h7q21, a known
human off-target site21, using a plasmid-based inversion assay. As in the selections the
proteins were expressed from the Pbad promoter. Since our theoretical model suggests that
greater accuracy is achieved at low protein expression levels, we grew the cells on
repressive LB/glucose medium. Indistinguishable results were achieved with growth on LB
in the absence of glucose. To test the mutants for improved accuracy we analyzed their
ability to recombine a known human pseudo-loxP site ψLox h7q21 and ψCore h7q21 (which
consists of inverted repeats from loxP but a spacer that matches ψLox h7q21F) (Fig. 3b).
Following recombination, substrate plasmids were isolated and digested in a way that
resulted in the substrate producing a 631 bp band and its inverted product producing a 386
bp band (Fig. 5a). Y324F produced only the 631 bp parent product while R32V, R32M, and
303GVSdup resulted in both inverted and parental plasmids (Fig. 5b). WT unexpectedly
produced the 898 bp band that corresponds to a deletion; there were no detectable bands for
the inverted and parental forms. We also observed a 1,795 bp band formed when ScaI failed
to cut. This product could be ignored for Y324F, R32V, R32M, and 303GVSdup because
ScaI cutting efficiency should be independent of cassette orientation. However the 1,795 bp
band did need to be taken into account when analyzing recombination by WT: we
normalized the 898 bp deletion product band to the total amount of DNA in the 898 bp and
1,795 bp bands (Figs. 5c & 5d). Incomplete ScaI digests also produced a 2,573 bp product
that is formed via an intermolecular insertion followed by inversion between recombination
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tsites that originated from different molecules (Supplementary Fig. S1). We excluded this
product from our analysis.
Achieving equilibrium in the inversion assay should result in 50% inversion. Recombination
of two loxP sites by R32V, R32M, and 303GVSdup resulted in approximately 50%
inversion and no detectable deletion products. In contrast, WT resulted in deletion in 98.7%
(95% CI: 97.5 – 100%) of plasmids (Fig. 5c). Unlike inversions, which can be reversed,
excisions are selected for in a dividing cell population because the excised products cannot
replicate. Therefore, the data should not be taken to mean that WT incorrectly excises nearly
100% of the time, but rather that the vast majority of substrate plasmids experienced at least
one excision event during the 12 hours of growth. Recombination by WT of pseudo-loxP
sites ψLox h7q21 and ψCore h7q21 resulted in improper excision with a frequency of 97.5%
(95% CI: 96.5–98.4%). R32V, R32M, and 303GVSdup produced no detectable
recombination products (Fig. 5d). In aggregate, the data provided evidence that the isolated
mutants are better able to distinguish on-target and off-target sites than WT.
Mutants are functional in vitro and in human cells
Given that in vivo recombination between two loxP sites reached equilibrium (~100%
deletion for WT and ~50% inversion for R32V, R32M, and 303GVSdup), there are two
explanations for the improved selectivity against pseudo-loxP sites observed for the mutant
recombinases; either the mutants were better able than WT to discriminate against pseudo-
loxP sites or the mutants were equally less efficient at recombining loxP and pseudo-loxP
sites than WT, but the high enzyme concentration and long reaction times were sufficient to
drive loxP recombination to completion. These two hypotheses can be distinguished by
comparing recombination of pseudo-loxP sites under conditions at which WT and mutants
have comparable, sub-equilibrium efficiencies of loxP recombination. Since such conditions
can be easily found in vitro we attempted to purify the WT and mutant Cre recombinases.
Affinity purification of using a maltose binding protein (MBP) domain fusion followed by
scarless protease cleavage of at the MBP domain allowed isolation of WT, R32V and R32M
(Supplementary Fig. S2). We attribute our failure to purify 303GVSdup to its lack of
solubility following MBP removal.
We measured recombination kinetics using an intramolecular excision assay on linearized
plasmid substrates. To test off-target activity we used a pseudo-loxP site lox80 (Fig. 3b),
which preliminary tests revealed to be efficiently recombined by WT in vitro. WT, R32V
and R32M were all able to recombine loxP within the 8 h assay. In contrast to WT, R32V
and R32M did not produce detectable loxPx lox80 reaction products (Figs. 6a–c). WT
recombination of the loxPx lox80 substrate produced a small amount of an unexpected
product that migrated at approximately twice the size of the linear recombination product.
This product, which we excluded from our quantitative analysis, may represent
recombination with a cryptic pseudo-loxP site in the vector backbone.
Cre recombined loxP x loxP and lox80 x loxP reactions with comparable kinetics, although
it was significantly less effective recombining lox80 at the 5 min time point (Figs. 5d and
5e). R32V and R32M recombined loxP sites significantly more slowly than WT, with both
mutants failing to achieve a steady state within the 8 h experiment. The kinetic data enabled
pseudo-loxP recombination efficiencies of the different mutants to be compared at similar
loxP x loxP recombination efficiencies. For instance, after 5 min WT had recombined loxP
sites with 21% efficiency, after 8 h R32V had recombined loxP sites with 29% efficiency,
and after 4 h R32M recombined the loxP substrate at an efficiency of 27%. Despite the
slightly higher loxP recombination efficiencies, R43V and R32M had no detectable off-
target activity while WT recombined lox80 and loxP with 4% efficiency. A similar
conclusion can be reached by comparing the 46% loxP x loxP efficiency and 35% lox80 ×
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tloxP achieved by WT after 30 min to the 44% loxP x loxP efficiency and absence of off-
target recombination seen with R32M after 8 h. In aggregate, these data support the model
under which the mutations we identified destabilize both loxP and pseudo-loxP
recombination, but with a much greater reduction in pseudo-loxP efficiency than in loxP
efficiency.
Our observation that R32V and R32M are functional in vitro suggested that the mutants, like
Cre, could catalyze loxP recombination in mammals. To test the functionality of Cre
mutants in human HEK293 cells we expressed R32V, R32M, and 303GVSdup under the
control of the CMV promoter. The substrate plasmid contained a loxP-flanked GFP with
downstream lacZ gene, such that recombination excised GFP and made the cells turn blue
when stained with X-gal (Supplementary Fig. 3a). 2.5 days following transfection with
R32V, R32M, and 303GVSdup the cells had lost the GFP signal and stained positive for β-
galactosidase activity (Supplementary Fig. 3b). As in E. coli, the in vivo reaction approached
completion; the transfection efficiency-normalized recombination efficiencies were 95.2%
for R32V (95% C.I.: 85.9 – 100%), 99% for R32M (95% C.I: 97.1 – 100%), and 100% for
303GVSdup (with no variation across replicates) (Supplementary Fig. 3c).
Mutants have less off-target activity genome-wide
One explanation for the improved accuracy we observed with R32V, R32M, and
303GVSdup is that the mutations altered the preferred off-target sites without changing the
overall accuracy. To test this possibility we measured the efficiency of off-target insertions
across the entire E. coli genome. Strains carrying the arabinose-inducible recombinase
expression plasmids were transformed with a plasmid containing a loxP site, an R6k γ origin
of replication, and a kanamycin resistance gene. Since the R6k γ origin cannot replicate in
the pir-strain we used, only insertion of the plasmid into the genome would result in the
replication of the kanamycin resistance gene. To control for variable transformation
efficiencies we normalized the number of R6k γ colonies by the number of colonies arising
from transformation with a plasmid lacking loxP but containing a functional origin of
replication.
We were unable to obtain Cre-mediated integration on LB/glucose. However, when we
briefly pulsed the cells with arabinose prior to the growth on LB/glucose, we obtained a
WT-mediated integration frequency of 1.3 × 10−4 (Table 1). 303GVSdup had an integration
frequency ~100-fold lower than WT. The integration frequencies of R32V and R32M were
lower than that of 303GVSdup and could not be distinguished from Y324F background.
These data strongly suggest that the higher accuracy of the mutants was not restricted to
loxBait, ψLox h7q21, and lox80.
Discussion
Our data suggest that R32V, R32M, and 303GVSdup can efficiently recombine loxP in
bacteria and in human cells. We also observed that the mutants exhibit better directionality
and better accuracy with respect to the pseudo-loxP site ψLox h7q21 than WT. R32V and
R32M were functional in vitro and were better able to discriminate against the lox80 site
than WT Cre. All three mutants more rarely integrated a loxP-carrying plasmid into the E.
coli genome than WT Cre. Crystal structures of Cre strongly suggest that R32V and R32M
disrupt a strong salt-bridge in the dimer interface (Fig. 4a). The duplicated residues in the de
novo 303GVSdup mutant are also located at the dimer interface, although the exact
biochemical consequences of the mutation are unclear.
Despite our model’s prediction that higher protein concentrations should reduces the
accuracy of recombination (Fig. 1), we saw identical results in our bacterial plasmid
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trecombination assay when the Pbad promoter controlling protein expression was repressed
with glucose (Figs. 5c, d) and when it was weakly induced by LB without glucose. Despite
the apparent contradiction, the data do not disprove the model. Even under glucose
repression WT Cre was able to drive both the loxP and pseudo-loxP reactions to equilibrium
within the time frame of the experiment, therefore any increases in recombination efficiency
caused by a higher protein concentrations could not be measured. The same logic applies to
R32V, R32M, and 303GVSdup recombining loxP sites. The model predicts that higher
protein concentrations should cause Cre mutants to recombine pseudo-loxP sites more
efficiently. The data neither confirm nor deny this prediction since both expression
conditions resulted in a recombination frequency that was below the detection level.
The main limitation of our accuracy model is that it considers only binding, ignoring
catalysis. The binding site sequence likely contributes to both establishing the proper
alignment of the catalytic site and creating a tertiary DNA structure within the recombinase
complex that is energetically favorable for recombination. The DNA site may also
contribute to protein folding35. It is therefore possible that R32V, R32M, and 303GVSdup
mutations contribute to improved accuracy in steps of the catalytic pathway other than DNA
binding. If that is the case, there may exist pseudo-loxP sites that are recombined by WT Cre
but not at all by the mutants.
Although R32V and R32M had high in vivo recombination efficiencies, the mutants
catalyzed recombination slower than WT in vitro (Fig. 6d). The slower kinetics may explain
some of the decrease in apparent off-target integration in the genome-wide assay (Table 1).
However, during the genome integration assay the cells were induced for 30 min and then
recovered for 1 h in glucose media prior to antibiotic selection. If it is assumed that
recombination occurred for 1 h (an underestimate since recombination can continue to
happen after the addition of antibiotics) then the in vitro data predict that R32V and R32M
will produce 10–20 fold fewer transformants than WT. In fact, R32V and R32M were at
least 200 times more accurate than WT. We therefore believe that the majority of the
decrease in the frequency of genomic integration was caused by an improvement in
selectivity against pseudo-loxP sites and not by the mutants’ slowed reaction kinetics.
Our observation that Cre make frequent deletions on a substrate containing inverted loxP has
been made previously36 and is consistent with the fact that Cre can occasionally recombine
sites with non-matching spacers30,31. This looseness in the directionality of recombination
may interfere with synthetic circuit designs that rely on Cre-mediated inversion as a form of
genetic memory37,38. The three Cre mutants we isolated seem to have an improved
directionality over WT and may therefore be of use in synthetic biology applications.
Since the binding specificity of nucleases is the major determinant of their toxicity, it may
be possible to minimize nucleases’ toxicity by reducing their DNA-binding cooperativity39.
The main limitation of this approach is the fact that it inevitably decreases affinity for the
target site. Strong monomer affinities, such as the 1–10 nM Kd of Cre for half of loxP32,40,
are a likely prerequisite. For comparison, DNA-binding domains composed of three Cys2-
His2 zinc fingers have been reported to bind to their 9 bp recognition sequence with a Kd as
low as 400 pM, while one 17.5 TALE repeat domain interacts with DNA with a Kd of 160
pM41,42. Although only the better zinc finger and TALE designs achieve such high binding
energies, the reported values suggest that destabilizing the cooperativity of DNA-binding
may be a viable strategy for increasing the accuracy of designer nucleases.
Changing the dimer interface has been previously used to improve the specificity of
nucleases engineered to cut asymmetrical DNA sites. Because targeting asymmetric sites
necessitates co-expression of two different DNA binding domains fused to a constant
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tnuclease domain, catalytically active dimers can format four different sites: the desired
asymmetric site, an off-target asymmetric site, and the two symmetric sites targeted by the
two possible homodimers. Converting the nuclease dimerization interface into a
heterodimeric interface reduces activity at the two symmetric off-target sites43–45. The
approach described in this paper is different from the obligate heterodimer strategy because
destabilizing the cooperativity of a dimeric protein improves accuracy by increasing the
energy difference between binding to the target and the off-target sites not by reducing the
number of possible target sites. The obligate heterodimer and the destabilized cooperativity
strategies should be compatible with each other as it should be possible to modulate the
binding cooperativity of heterodimers.
Due to its high efficiency and the lack of necessary co-factors, Cre has found widespread
use in genetics research46. However, Cre toxicity in the absence of loxP sites has been
observed in a variety of animal and cell culture systems47–51. The source of this toxicity is
not known. However, a number of observations, including absence of toxicity from
catalytically inactive Cre mutants, an increase in the frequency of chromosomal
rearrangements, and evidence of activation of DNA damage response pathways all point at
recombination at off-target pseudo-loxP sites as the cause47,49–51. We envision that the Cre
mutants isolated in this study may be useful for alleviating the toxic phenotypes associated
with WT Cre. This approach should be compatible with existing strategies for reducing Cre
toxicity, which include placing the Cre gene in a self-excisable cassette, regulating Cre
activity with a hormone binding domain of a steroid receptor, or using a drug-regulated
fragment complementation strategy50,52–54.
Methods
Plasmid construction
The positive selection substrate pCR-(loxP-ampR-loxPinv)inv was built by amplifying ampR
from pQL12355 with primers ampR_f and ampR_r (primer sequences are provided in
Supplementary Table S1), performing an extension PCR on the amplicon with ampR_loxP_f
and ampR_loxP_inv_r, and TOPO cloning the product into pCR-Blunt II-TOPO (Life
Technologies). Sequencing was used to screen for colonies in which the ampR gene was in
reverse orientation with respect to the promoter. A similar workflow was used to construct
pCR-(h7q21-ampR-ψlox h7q21inv)inv, pCR-(lox80-ampR-loxP)inv, and pCR-loxBait-ampR-
loxP. The pZE2-loxP/loxP and and pZE2-ψCore h7q21/ψlox h7q21 in vivo recombination
substrates were obtained by cloning the XhoI/BamHI fragment from pCR-(loxP-ampR-
loxPinv)inv or pCR-(h7q21-ampR-ψlox h7q21inv)inv into XhoI/BamHI-digested pZE21G.
The Cre gene was obtained from pQL123, though we reverted the alanine at the second
position to the serine found in WT Cre (GenBank sequence YP_006472). For the bacterial
assays the Cre mutants or libraries were introduced in place of HpaII[51-358] in pARC8-
HpaII[51-358](a derivative of pAR-MHhaI[29–327]56 containing residues 51-358 of HpaII
in the place of HhaI) using Gibson assembly57. Cloning was performed with a backbone
amplified using primers pARC8_f and pARC8_r. For protein purification WT, R32V,
R32M, and 303GVSdup were amplified from the respective pARC8-based plasmids using
primers Cre_not ATG_f and Cre_SalI_r. The genes were digested with SalI and ligated into
SalI/XmnI-digested pMAL-c5x (New England Biolabs). For mammalian expression R32V,
R32M, and 303GVSdup were amplified from the corresponding pARC8-based expression
plasmids using primers Cre_TA_f and Cre_TA_r and TOPO TA cloned into pcDNA3.3-
TOPO (Life Technologies). Clones were screened for the correct orientation by PCR.
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Libraries of half-site variants were constructed by amplifying the pZE21G plasmid58 first
with primers pZE21G_f and pZE21G_r, and then pZE21G_2_lib and pZE21G_2_loxP,
producing an amplification product that was 2,437 bp long and contained a loxP site and a
random library site near each end. The libraries were purified using the QIAquick PCR
Purification Kit (Qiagen), 10–20 ng of the DNA was treated with 1 U Cre (New England
Biolabs) in Cre reaction buffer (10 mM MgCl2, 33 mM NaCl, 50 mM Tris-HCl pH 7.5) in
20 μL total reaction volume for 1 hr at 37 °C, heat inactivated at 75–80 °C, then digested
with DpnI. The DNA was then purified, digested with PlasmidSafe (Epicentre), and
transformed into One Shot Top10 chemically competent cells (Life Technologies, recA1
araD139Δ(ara-leu)7697 Δ(lac)X74). Colonies were randomly selected for sequencing.
Substrates for validating the selection hits were generated by performing extension PCR on
pZE21G as for the selections except that sequences obtained from the selection were in
place of the random library. 30 ng of purified products were treated with 1 U Cre in Cre
reaction buffer in 20 μL total reaction volume for 1.5 hr at 37 °C followed by heat
inactivation of the enzyme. The entire reaction was resolved on a 0.7% agarose gel stained
with SYBR Green I (Life Technologies). Each recombination was performed in parallel with
a no-enzyme negative control.
Negative and positive selections
The pCR-(loxP-ampR-loxPinv)inv and pCR-loxBait-ampR-loxP selection plasmids were
maintained in NEB 10-beta cells (New England Biolabs, recA1 araD139 Δ(ara-leu)7697
Δ(lac)X74); cells were made electrocompetent using standard techniques59. The library of
Cre variants was generated by mutagenic PCR using a pool of 19 oligonucleotides that
substituted each of the 19 codons encoding S20–S38 for NNN (1st round of PCR: primers
Cre_mut_1 – Cre_mut_19 and Cre_pARC8_r; 2nd round of PCR: primers Cre_pARC8_f
and Cre_pARC8_r). The library was introduced into pARC8 using Gibson assembly,
desalted by drop dialysis, and electroporated into competent cells carrying pCR-(loxP-
ampR-loxPinv)inv. Control transformations were performed with 100 pg pARC8-Cre or
pARC8-Y324F. Transformed cells were recovered in low-salt 2X LB (2% bacto-tryptone,
1% yeast extract, 0.5% NaCl, pH 7.5) at 37 °C for 30 min, induced with 0.2% arabinose at
37 °C for 30 min, and recovered in SOC with 200 μM IPTG at 37 °C for 1 hr. The cells
were then grown overnight at 37 °C on 0.2% glucose, 100 μM IPTG, 12.5 μg/mL
chloramphenicol, 50μg/mL kanamycin LB plates either with or without 100 μg/mL
carbenicillin.
Colonies obtained from the positive selection of the library and of the controls were
collected by scraping. DNA was isolated using the QIAprep Spin Miniprep kit (Qiagen) and
was digested with XmaI and SpeI (which cut only the substrate plasmids.) The concentration
of expression plasmid was quantified via agarose gels. Electrocompetent cells carrying the
pCR-loxBait-ampR-loxP negative selection substrate were transformed with 100 pg of the
expression plasmid, recovered the cells in low-salt 2X LB for at 28 °C for 30 min, induced
with 0.2% arabinose at 28 °C for 30 min, washed with SOC, and recovered in SOC with 200
μM IPTG at 37 °C for 1 hr. The cells were then grown overnight at 37 °C on 0.2% glucose,
100 μM IPTG, 12.5 μg/mL chloramphenicol, 50 μg/mL kanamycin, 100 μg/mL carbenicillin
LB plates. To ensure clonality the isolated variants were amplified and re-cloned into
pARC8 via Gibson assembly.
Bacterial recombination assay
Efficiencies were measured by co-transforming 75 ng of a pARC8-based expression plasmid
(WT, Y324F, R32V, R32M, or 303GVSdup) and an equimolar amount of either pZE2-loxP/
loxP or pZE2-ψCore h7q21/ψlox h7q21 into 50 μL vial of OneShot Top10 chemically
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grown at 37 °C for 12 hrs in 0.2% glucose, 12.5 μg/mL chloramphenicol, 50 μg/mL
kanamycin LB. The plasmids were isolated using the QIAprep Spin Miniprep kit, eluting
into 50 μL10 mM Tris-HCl pH 8. The purified plasmids were digested for 20 min at 37 °C
in 60 μL reactions containing all of the collected DNA and 20 U of both ScaI-HF and NcoI-
HF (both from New England Biolabs) in NEBuffer 4 (1 mM DTT, 50 mM potassium
acetate, 20 mM tris-acetate, 10 mM magnesium acetate, pH 7.9). The digests quantified on
1% agarose gels following purification using the QIAprep Spin Miniprep kit.
In vitro recombination assay
The pMAL-based recombinase expression plasmids were maintained in One Shot Top10
chemically competent cells. An overnight culture of each expression clone was diluted to
OD600 of 0.02 in 55 mL 0.2% glucose, 50 μg/mL kanamycin LB and grown for 2.5 hrs at
37 °C. IPTG was added to a final concentration of 300 μM and the cultures were grown at
37 °C for an additional 2 hrs. 50 mL of the culture was pelleted, resuspended in 5 mL lysis
buffer (1 mM EDTA, 1 mM DTT, 200 mM NaCl, 20 mM Tris-HCl pH 8) supplemented
with Halt Protease Inhibitor Cocktail (Thermo Scientific). The cell suspension lysed using
eight 15 sec sonication cycles using a power setting of 4 on a Misonix Sonicator 3000. The
lysate was centrifuged for 20 min at 5,000 g and the supernate was bound to 500 uL amylose
resin (New England Biolabs). The resin was washed with 4 mL wash buffer (200 mM NaCl,
20 Tris-HCl pH 7.5), 12 mL of DNA-removal buffer (1 M NaCl, 20 mM Tris-HCl pH 7.5),
and again with 4 mL wash buffer. The protein was eluted into 500 μL elution buffer (0.5%
maltose, 2 mM CaCl2, 100 mM NaCl, 20 mM Tris-HCl pH 7.5) and digested with 200 ng
Factor Xa (New England Biolabs) for 13–14 hrs at room temperature. The protease activity
was stopped by adding Halt Inhibitors to 1× and DTT to 1 mM. Precipitated protein was
removed by centrifuging at 16,000 g for 10 min and passing the supernate through an
Amicon Ultracel 100K filter. The flow-through was concentrated using an Amicon Ultracel
10K filter. Glycerol was added to 27% final volume, NaCl was added to adjust the
concentration to 200 mM, and the proteins were stored at −20 °C. Catalytic assays were
performed within 2 days of purification. Protein concentration was determined using a Qubit
2.0 fluorometer (Life Technologies). The concentration of protease-cleaved recombinase
was determined by quantifying band intensity on a SimplyBlue (Life Technologies) stained
PAGE gel (typical values were 15–30%), and by then normalizing the total protein
concentration by the obtained value.
Linearized pLox2+ (New England Biolabs) and ScaI-digested pCR-(lox80-ampR-loxP)inv
were used as the recombination substrates. Recombination kinetics were measured by
reacting 5 nM of the DNA substrate and 750 nM of each protease-cleaved recombinase in
Cre reaction buffer with 100 ng/μL BSA. The reactions were performed at 37 °C and were
stopped by heating them to 70 °C for 15–25 min. Excision was measured by quantifying
bands on 1% agarose gels.
Human cell culture recombination assay
pCMV:GFP(loxP)lacZ60 (Addgene: 31125) was used as the recombination substrate
plasmid and pcDNA3.3-TOPO/lacZ (Life Technologies) was used as a lacZ staining control.
Except for pcDNA3.3-TOPO/lacZ, which was prepared by the manufacturer, all substrate
and expression plasmids were prepared for transfection using the HiSpeed Plasmid Maxi Kit
(Qiagen).
Lenti-X 293T cells (Clontech) were grown on poly-D-lysine coated tissue-culture treated
polystyrine in DMEM High Glucose with GlutaMAX (Life Technologies) supplemented
with 10% FBS, 50 U/mL penicillin, and 50 ug/mL streptomycin at 37 °C and 5% CO2 in a
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thumidified incubator. Cells were subcultured using TrypLE Express (Life Technologies).
Cells in 12-well plates were transformed with 500 ng pCMV:GFP(loxP)lacZ and 500 ng
pcDNA3.3-TOPO-based expression plasmid using Fugene HD (Promega). Substrate only-
controls were transformed with only 500 ng recombination substrate and the lacZ controls
were trasfromed with 500 ng pcDNA3.3-TOPO/lacZ. Media was changed 1 d following
transfection. Cells were subcultured 2 d following transfection. Staining and imaging was
performed 2.5 d following transfection. Cells were fixed using 2% formaldehyde and 0.1%
glutaraldehyde in PBS for 10 min at room temperature. After being washed with PBS the
cells were stained with 1 mg/mL X-gal, 4 mM potassium ferricyanide, 4 mM potassium
ferrocyanide, and 2 mM MgCl2 in PBS for 30 min at 37 °C. Following staining the cells
were washed with PBS and imaged.
Genome-wide off-target integration assay
Electrocompetent cells were prepared from each of the pARC8-based expression plasmids
(WT, Y324F, R32V, R32M, or 303GVSdup) cloned in NEB 10-beta cells using 40 mL of
culture per transformation. Each expression strain was transformed either with 200 ng
pUNI10 (loxP+, oriR6Kγ, kanR)55 or an equimolar amount of pZE21G (loxP−, oriColE1,
kanR). The two transformations were done in parallel using competent cells made from
aliquots of the same culture. The cells were recovered in LB for at 37 °C for 30 min,
induced with 0.2% arabinose at 37°C for 30 min, and recovered in SOC at 37 °C for 1 hr.
The cells were then grown overnight at 37 °C on 0.2% glucose, 12.5 μg/mL
chloramphenicol, 50 μg/mL kanamycin LB plates.
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Acknowledgments
This work was supported by the US Office of Naval Research Multidisciplinary University Initiative and the
National Human Genome Research Institute Center for Excellence in Genomics Science. We thank G. Meister for
pARC8-HpaII[51-358] and S. Elledge for pQL123 and pUNI10. We also thank P. Mali, J. DiCarlo and A.
McElhinney for a critical reading of the manuscript and S. Kosuri, S. Raman, M. Lajoie and X. Rios for helpful
advice and inspiring discussions.
References
1. Stocking C, et al. Distinct classes of factor-independent mutant can be isolated after retroviral
mutagenesis of a human myeloid stem cell line. Growth Factors. 1993; 8:197–209. [PubMed:
8391284]
2. Hacein-Bey-Abina S, et al. A aerious adverse event after successful gene therapy for X-Linked
severe combined immunodeficiency. New England Journal of Medicine. 2003; 348:255–256.
[PubMed: 12529469]
3. Rouet P, Smih F, Jasin M. Introduction of double-strand breaks into the genome of mouse cells by
expression of a rare-cutting endonuclease. Molecular and Cellular Biology. 1994; 14:8096–8106.
[PubMed: 7969147]
4. Kim YG, Cha J, Chandrasegaran S. Hybrid restriction enzymes: zinc finger fusions to Fok I
cleavage domain. Proceedings of the National Academy of Sciences. 1996; 93:1156–1160.
5. Li T, et al. TAL nucleases (TALNs): hybrid proteins composed of TAL effectors and FokI DNA-
cleavage domain. Nucleic Acids Research. 2010; 39:359–372. [PubMed: 20699274]
6. Christian M, et al. Targeting DNA double-strand breaks with TAL effector nucleases. Genetics.
2010; 186:757–761. [PubMed: 20660643]
7. Cong L, et al. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013; 339:819–
823. [PubMed: 23287718]
Eroshenko and Church Page 11
Nat Commun. Author manuscript; available in PMC 2014 April 01.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t8. Mali P, et al. RNA-guided human genome engineering via Cas9. Science. 2013; 339:823–826.
[PubMed: 23287722]
9. Mao Z, Bozzella M, Seluanov A, Gorbunova V. Comparison of nonhomologous end joining and
homologous recombination in human cells. Journal of Molecular Biology. 2008; 7:1765–1771.
10. Hartlerode AJ, Scully R. Mechanisms of double-strand break repair in somatic mammalian cells.
Biochemical Journal. 2009; 423:157–168. [PubMed: 19772495]
11. Grindley NDF, Whiteson KL, Rice PA. Mechanisms of site-specific recombination. Annual
Review of Biochemistry. 2006; 75:567–605.
12. Buchholz F, Stewart AF. Alteration of Cre recombinase site specificity by substrate-linked protein
evolution. Nature Biotechnology. 2001; 19:1047–1052.
13. Sclimenti CR, Thyagarajan B, Calos MP. Directed evolution of a recombinase for improved
genomic integration at a native human sequence. Nucleic Acids Research. 2001; 29:5044–5051.
[PubMed: 11812835]
14. Santoro SW, Schultz PG. Directed evolution of the site specificity of Cre recombinase.
Proceedings of the National Academy of Sciences. 2002; 99:4185–4190.
15. Akopian A, He J, Boocock MR, Stark WM. Chimeric recombinases with designed DNA sequence
recognition. Proceedings of the National Academy of Sciences. 2003; 100:8688–8691.
16. Gordley RM, Smith JD, Graslund T, Barbas CF III. Evolution of programmable zinc finger-
recombinases with activity in human cells. Journal of Molecular Biology. 2007; 367:802–813.
[PubMed: 17289078]
17. Sarkar I, Hauber I, Hauber J, Buchholz F. HIV-1 proviral DNA excision using an evolved
recombinase. Science. 2007; 316:1912–1915. [PubMed: 17600219]
18. Keravala A, et al. Mutational derivatives of PhiC31 integrase with increased efficiency and
specificity. Molecular Therapy. 2009; 17:112–120. [PubMed: 19002165]
19. Gersbach CA, Gaj T, Gordley RM, Barbas CF. Directed evolution of recombinase specificity by
split gene reassembly. Nucleic Acids Research. 2010; 38:4198–4206. [PubMed: 20194120]
20. Abi-Ghanem J, et al. Engineering of a target site-specific recombinase by a combined evolution-
and structure-guided approach. Nucleic Acids Research. 2012; 41:2394–2403. [PubMed:
23275541]
21. Thyagarajan B, Guimaraes MJ, Groth AC, Calos MP. Mammalian genomes contain active
recombinase recognition sites. Gene. 2000; 244:47–54. [PubMed: 10689186]
22. Thyagarajan B, Olivares EC, Hollis RP, Ginsburg DS, Calos MP. Site-specific genomic integration
in mammalian cells mediated by phage phiC31 integrase. Molecular and Cellular Biology. 2001;
21:3926–3934. [PubMed: 11359900]
23. Keravala A, et al. A diversity of serine phage integrases mediate site-specific recombination in
mammalian cells. Molecular Genetics and Genomics. 2006; 276:135–146. [PubMed: 16699779]
24. Semprini S, et al. Cryptic loxP sites in mammalian genomes: genome-wide distribution and
relevance for the efficiency of BAC/PAC recombineering techniques. Nucleic Acids Research.
2007; 35:1402–1410. [PubMed: 17284462]
25. Nelson HCM, Sauer RT. Interaction of mutant λ repressors with operator and non-operator DNA.
Journal of Molecular Biology. 1986; 192:27–38. [PubMed: 2950238]
26. Sternberg N, Hamilton D. Bacteriophage P1 site-specific recombination. I. Recombination between
loxP sites. Journal of Molecular Biology. 1981; 150:467–486. [PubMed: 6276557]
27. Hoess RH, Ziese M, Sternberg N. P1 site-specific recombination: nucleotide sequence of the
recombining sites. Proceedings of the National Academy of Sciences. 1982; 79:3398–3402.
28. Van Duyne GD. A structural view of cre-loxp site-specific recombination. Annual Reviews of
Biophysics and Biomolecular Structure. 2001; 30:87–104.
29. Hartung M, Kisters-Woike B. Cre mutants with altered DNA binding properties. The Journal of
Biological Chemistry. 1998; 273:22884–22891. [PubMed: 9722507]
30. Missirlis PI, Smailus DE, Holt RA. A high-throughput screen identifying sequence and
promiscuity characteristics of the loxP spacer region in Cre-mediated recombination. BMC
Genomics. 2006; 7:73. [PubMed: 16595017]
Eroshenko and Church Page 12
Nat Commun. Author manuscript; available in PMC 2014 April 01.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t31. Sheren J, Langer SJ, Leinwand LA. A randomized library approach to identifying functional lox
site domains for the Cre recombinase. Nucleic Acids Research. 2007; 35:5464–5473. [PubMed:
17702764]
32. Rufer A, Neuenschwander PF, Sauer B. Analysis of Cre loxP interaction by surface plasmon
resonance: Influence of spermidine on cooperativity. Analytical Biochemistry. 2002; 308:90–99.
[PubMed: 12234468]
33. Jen-Jacobson L. Protein-DNA recognition complexes: conservation of structure and binding
energy in the transition state. Biopolymers. 1997; 44:153–180. [PubMed: 9354759]
34. Guo F, Gopaul D, Van Duyne G. Structure of Cre recombinase complexed with DNA in a site-
specific recombination synapse. Nature. 1997; 389:40–46. [PubMed: 9288963]
35. Shoemaker BA, Portman JJ, Wolynes PG. Speeding molecular recognition by using the folding
funnel: the fly-casting mechanism. Proc Natl Acad Sci USA. 2000; 97:8868–8873. [PubMed:
10908673]
36. Aranda M, et al. Altered directionality in the cre-loxP site-specific recombination pathway. Journal
of Molecular Biology. 2001; 311:453–459. [PubMed: 11492999]
37. Livet J, et al. Transgenic strategies for combinatorial expression of fluorescent proteins in the
nervous system. Nature. 2007; 450:56–62. [PubMed: 17972876]
38. Friedland AE, et al. Synthetic gene networks that count. Science. 2009; 324:1199–1202. [PubMed:
19478183]
39. Cornu TI, et al. DNA-binding specificity is a major determinant of the activity and toxicity of zinc-
finger nucleases. Molecular Therapy. 2007; 16:352–358. [PubMed: 18026168]
40. Ringrose L, et al. Comparative kinetic analysis of FLP and cre recombinases: mathematical models
for DNA binding and recombination. Journal of Molecular Biology. 1998; 284:363–384.
[PubMed: 9813124]
41. Segal DJ, Dreier B, Beerli RR, Barbas CF III. Toward controlling gene expression at will:
selection and design of zinc finger domains recognizing each of the 5′-GNN-3′ DNA target
sequences. Proceedings of the National Academy of Sciences. 1999; 96:2758–2763.
42. Meckler JF, et al. Quantitative analysis of TALE-DNA interactions suggests polarity effects.
Nucleic Acids Research. 2013; 41:4118–4128. [PubMed: 23408851]
43. Miller JC, et al. An improved zinc-finger nuclease architecture for highly specific genome editing.
Nature Biotechnology. 2007; 25:778–785.
44. Szczepek M, et al. Structure-based redesign of the dimerization interface reduces the toxicity of
zinc-finger nucleases. Nature Biotechnology. 2007; 25:786–793.
45. Doyon Y, et al. Enhancing zinc-finger-nuclease activity with improved obligate heterodimeric
architectures. Nature Methods. 2011; 8:74–79. [PubMed: 21131970]
46. Branda CS, Dymecki SM. Talking about a revolution: The impact of site-specific recombinases on
genetic analyses in mice. Developmental Cell. 2004; 6:7–28. [PubMed: 14723844]
47. Schmidt EE, Taylor DS, Prigge JR, Barnett S, Capecchi MR. Illegitimate Cre-dependent
chromosome rearrangements in transgenic mouse spermatids. Proceeedings of the National
Academy of Sciences. 2000; 97:13702–13707.
48. Heidmann D, Lehner CF. Reduction of Cre recombinase toxicity in proliferating Drosophila cells
by estrogen-dependent activity regulation. Development Genes and Evolution. 2001; 211:458–
465. [PubMed: 11685583]
49. Loonstra A, et al. Growth inhibition and DNA damage induced by Cre recombinase in mammalian
cells. Proceedings of the National Academy of Sciences. 2001; 98:9209–9214.
50. Silver DP, Livingston DM. Self-excising retroviral vectors encoding the Cre recombinase
overcome Cre-mediated cellular toxicity. Molecular Cell. 2001; 8:233–243. [PubMed: 11511376]
51. Huh WJ, Mysorekar IU, Mills JC. Inducible activation of Cre recombinase in adult mice causes
gastric epithelial atrophy, metaplasia, and regenerative changes in the absence of ‘floxed’ alleles.
American Journal of Physiology - Gastrointestinal and Liver Physiology. 2010; 299:G368–80.
[PubMed: 20413717]
52. Feil R, et al. Ligand-activated site-specific recombination in mice. Proceedings of the National
Academy of Sciences. 1996; 93:10887–10890.
Eroshenko and Church Page 13
Nat Commun. Author manuscript; available in PMC 2014 April 01.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t53. Kellendonk C, et al. Regulation of Cre recombinase activity by the synthetic steroid RU 486.
Nucleic Acids Research. 1996; 24:1404–1411. [PubMed: 8628671]
54. Jullien N, Sampieri F, Enjalbert A, Herman JP. Regulation of Cre recombinase by ligand-induced
complementation of inactive fragments. Nucleic Acids Research. 2003; 31:e131. [PubMed:
14576331]
55. Liu Q, Li MZ, Leibham D, Cortez D, Elledge SJ. The univector plasmid-fusion system, a method
for rapid construction of recombinant DNA without restriction enzymes. Current Biology. 1998;
8:1300–1309. [PubMed: 9843682]
56. Choe W, Chandrasegaran S, Ostermeier M. Protein fragment complementation in M.HhaI DNA
methyltransferase. Biochem Biophys Res Commun. 2005; 334:1233–1240. [PubMed: 16040000]
57. Gibson DG, et al. Enzymatic assembly of DNA molecules up to several hundred kilobases. Nature
Methods. 2009; 6:343–345. [PubMed: 19363495]
58. Isaacs FJ, et al. Engineered riboregulators enable post-transcriptional control of gene expression.
Nature Biotechnology. 2004; 22:841–847.
59. Sambrook, J.; Russell, DW. Molecular Cloning: a Laboratory Manual. 2001.
60. Werdien D, Peiler G, Ryffel GU. FLP and Cre recombinase function in Xenopus embryos. Nucleic
Acids Research. 2001; 29:E53–3. [PubMed: 11376165]
Eroshenko and Church Page 14
Nat Commun. Author manuscript; available in PMC 2014 April 01.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tFigure 1. Model predicting an increase in Cre recombinase dimer binding accuracy as
cooperativity decreases
The solid line indicates the accuracy predicted for WT Cre, while the dashed lines
correspond to the expected accuracy of mutants in which the energy in the protein-protein
interface has been reduced by the indicated amount.
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tFigure 2. Selecting functional and accurate Cre variants
a) The substrate used to select for functional variants; proper recombination would place the
ampicillin resistance gene (ampR) under the lac promoter (Plac)conferring resistance. The
ccdB gene is crossed out to indicate that it’s out of frame with respect to the ampR start
codon. b) Ratio of ampicillin resistant to the total number of colonies isolated following the
positive selection. c) The substrate used to select for accurate variants - recombination of
loxP and loxBait sites would result in loss of ampicillin resistance and would place the toxic
ccdB gene in frame with the promoter. d) Number of ampicillin resistant colonies recovered
from the negative selection.
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tFigure 3. Activity and nomenclature of pseudo-loxP sites
a) Linear fragments with loxP onone end and the indicated sites on the other were treated
with Cre and the products were quantified on an agarose gel. All new bands were counted
towards the recombination efficiency. No recombination was observed for any of the sites in
the absence of Cre. Bolded positions correspond to differences from loxP. Sites are listed in
order of similarity with loxP. Asterisks mark sequences generated randomly; all others were
obtained from a selection for functional pseudo-loxP sites. The box indicates loxBait. b) The
names and sequences of recombination sites used in this study. Positions that are different
from loxP are shown in bold. Error bars correspond to 95% C.I. (n = 2–3 experimental
replicates).
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tFigure 4. Structural context of the isolated mutants
a) R32V and R32M disrupt a putative salt bridge between two monomers (shown in blue
and green) at R32 and E69. The two residues are shown as stick structures colored by atom
identity (blue - N; red - O; gray - C). b) 303GVSdup duplicated the loop shown in orange.
One of the monomers is shown as a space-filling model. The catalytic site residues (R173,
H289, R292, W315, Y324) are shown as stick figures. The crystallographic data was
obtained from PDB 3C29.
Eroshenko and Church Page 18
Nat Commun. Author manuscript; available in PMC 2014 April 01.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tFigure 5. In vivo recombination of plasmids by mutants of Cre
a) Plasmid architecture of the three expected recombination products. Recombination sites
are shown as triangles. For simplicity, the map is in linear form, where the NcoI sites at the
ends represent a single NcoI site on the circular plasmids. The numbers under each segment
indicate distance in bp (map not drawn to scale). The numbers adjacent to each map are the
sizes of the expected digestion products, with the asterisks indicating the product size that is
unique to the particular configuration. b) Digest analysis of loxP x loxP (left five lanes) and
ψlox h7q21 x ψCore h7q21 (right five lanes) recombination. (c& d) Inversion and
recombination frequency of (c) loxP x loxP and (d) ψCore h7q21 x ψlox h7q21
recombination obtained by quantifying band intensities. Error bars correspond to 95% C.I.
(n= 2 independent experiment). NI: NcoI site; SI: ScaI site.
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tFigure 6. In vitro recombination of plasmids by mutants of Cre
a) WT Cre purification of loxP x loxP (left) and lox80 x loxP substrates was performed for
the indicated amount of time and resolved on an agarose gel. The linearized substrate
plasmid contained two recombination sites such that catalysis resulted produced a circular
and a short linear fragment. The same conditions were used to test b) R32V and c) R32M.
The band intensities were quantified and plotted for d) loxP x loxP and e) lox80 x loxP
recombination. Error bars correspond to 95% C.I. (n = 2–4 experiments using different
protein preparations).
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Table 1
Genome-wide off-target integration frequency
Insertion frequency corresponds to the ratio of loxP+ to loxP− colonies. 95% C.I. were computed using the
Poisson variance. The data represent pooled observations from 3–4 independent experiments.
loxP+ ori- kanR colonies loxP- ori+ kanR colonies loxP insertion frequency 95% C.I.
Y324F 1 6.2 × 106 1.6 × 10−7 0 – 4.8 × 10−7
WT 1,025 8.1 × 106 1.3 × 10−4 1.2 × 10−4 – 1.4 × 10−4
R32V 2 9.4 × 106 2.1 × 10−7 0 – 5.1 × 10−7
R32M 3 6.3 × 107 4.8 × 10−8 0 – 1 × 10−7
303GVSdup 46 2.6 × 107 1.7 × 10−6 1.2 × 10−6 – 2.2 × 10−6
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